恐慌症治療市場分析及預測（至2035年）：依類型、產品類型、服務、技術、應用、最終使用者、模式及階段分類

預計到2034年，恐慌症治療市場規模將從2024年的31億美元成長至137億美元，複合年成長率約為15.2%。恐慌症治療市場涵蓋旨在緩解恐慌症症狀的治療方法和藥物，例如認知行為療法、抗憂鬱症和苯二氮平類藥物。該市場的成長主要受心理健康意識的提高和焦慮症盛行率的上升所驅動。創新重點在於個人化治療方案和數位療法，同時，遠端醫療解決方案也日益受到重視，以提高治療的可及性和有效性。隨著社會對恐慌症的歧視逐漸消除以及醫療技術的不斷進步，該領域有望持續成長。

由於人們對焦慮症的認知不斷提高，以及焦慮症盛行率的上升，恐慌症治療市場預計將迎來強勁成長。藥物是該市場的主導部分，其中選擇性血清素再回收抑制劑（SSRIs）因其高效性而成為最大的細分市場。苯二氮平類藥物緊追在後，能夠快速緩解急性恐慌症狀。心理療法，尤其是認知行為療法（CBT），是表現第二好的細分市場，並作為長期治療策略日益受到重視。新興的數位治療方法，包括行動應用程式和遠距治療平台，正逐漸普及，以滿足人們對便利治療方案的需求。將虛擬實境（VR）技術融入治療過程是一種創新趨勢，它透過身臨其境型體驗來緩解症狀。正念和瑜珈等輔助和替代療法也越來越被人們接受，並有助於改善整體健康。市場正在加大對研發的投資，專注於個人化醫療方法，旨在最佳化治療效果並提高患者的生活品質。

恐慌症治療市場的特點是治療方案多樣化，包括藥物和認知療法。市場佔有率主要由大型製藥企業主導，其定價策略與品牌聲譽和療效密切相關。近期推出的新產品專注於創新給藥方式和新型化合物，以提高患者依從性和治療效果。藥物基因組學和數位健康技術的進步正在推動治療方案轉向個人化。恐慌症治療市場的競爭異常激烈，主要企業透過策略性併購主導。基準研究顯示，市場呈現專業化和細分市場化的趨勢。法規結構，尤其是在北美和歐洲，十分嚴格，影響市場動態和產品核可。資料隱私法規對數位治療解決方案產生影響，需要製定強而有力的合規策略。儘管面臨監管合規挑戰和競爭壓力，但受意識提升和技術創新的推動，該市場仍呈現出成長勢頭。

主要趨勢和促進因素：

受心理健康意識提升和焦慮症發病率上升的推動，恐慌症治療市場正經歷強勁成長。關鍵趨勢包括治療模式（例如數位療法和遠端醫療）的技術進步，這些進步提高了患者的就醫便利性。人工智慧與診斷工具的融合進一步實現了治療的個人化，並滿足了日益成長的個人化醫療保健解決方案需求。製藥業的創新也正在推動市場擴張，新型藥物配方和非侵入性療法正獲得廣泛認可。正念療法和認知行為療法等替代療法的日益普及，促進了整體治療方法的轉變。監管支持和消除心理健康問題污名化的努力也是關鍵促進因素，為市場成長創造了有利環境。此外，新興經濟體心理健康基礎設施的快速發展也帶來了市場機會。能夠提供經濟高效且擴充性的治療方案的公司，將佔據有利地位，在這個快速成長的市場中獲利。隨著人們對心理健康治療的認知和接受度不斷提高，恐慌症治療市場預計將持續成長，尤其是在那些將心理健康視為整體健康關鍵組成部分的地區。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

• 宏觀經濟分析
• 市場趨勢
• 市場促進因素
• 市場機遇
• 市場限制
• 複合年均成長率：成長分析
• 影響分析
• 新興市場
• 技術藍圖
• 戰略框架

第4章 細分市場分析

• 市場規模及預測：依類型
  • 藥物治療
  • 認知行為療法
  • 正念療法
  • 暴露療法
  • 接納與承諾療法
  • 心理動力療法
  • 支持性護理
• 市場規模及預測：依產品分類
  • 選擇性血清素再回收抑制劑（SSRIs）
  • SNRIs（血清素-正腎上腺素再回收抑制劑）
  • 苯二氮平類藥物
  • BETA阻斷劑
  • 抗憂鬱症
  • 治療應用程式
  • 穿戴式裝置
• 市場規模及預測：依服務分類
  • 住院治療
  • 門診治療
  • 遠距治療
  • 團體治療
  • 個別治療
  • 緊急服務
• 市場規模及預測：依技術分類
  • 行動醫療技術
  • 遠端醫療平台
  • 基於人工智慧的診斷
  • 虛擬實境療法
• 市場規模及預測：依應用領域分類
  • 應對急性恐慌發作
  • 長期焦慮管理
  • 預防復發
• 市場規模及預測：依最終用戶分類
  • 醫院
  • 精神健康診所
  • 居家醫療環境
  • 學術和研究機構
• 市場規模及預測：依實施方法分類
  • 處方箋治療
  • 非處方藥
  • 數位平台
• 市場規模及預測：依疾病階段分類
  • 初步診斷
  • 開始治療
  • 維持治療
  • 後續

第5章 區域分析

• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 其他拉丁美洲地區
• 亞太地區
  • 中國
  • 印度
  • 韓國
  • 日本
  • 澳洲
  • 台灣
  • 亞太其他地區
• 歐洲
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 義大利
  • 其他歐洲地區
• 中東和非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非
  • 撒哈拉以南非洲
  • 其他中東和非洲地區

第6章 市場策略

• 需求與供給差距分析
• 貿易和物流限制
• 價格、成本和利潤率趨勢
• 市場滲透率
• 消費者分析
• 法規概述

第7章 競爭訊息

• 市場定位
• 市場占有率
• 競爭基準
• 主要企業的策略

第8章 公司簡介

• Mind Med
• Alkermes
• Sage Therapeutics
• Axsome Therapeutics
• Intra-Cellular Therapies
• Vista Gen Therapeutics
• Relmada Therapeutics
• Biohaven Pharmaceuticals
• Cerevel Therapeutics
• Karuna Therapeutics
• Minerva Neurosciences
• Otsuka Pharmaceutical
• Jazz Pharmaceuticals
• H. Lundbeck
• Neurocrine Biosciences
• ACADIA Pharmaceuticals
• Sunovion Pharmaceuticals
• Eisai
• Vanda Pharmaceuticals
• Supernus Pharmaceuticals

第9章：關於我們

Panic Attack Treatment Market is anticipated to expand from $3.1 billion in 2024 to $13.7 billion by 2034, growing at a CAGR of approximately 15.2%. The Panic Attack Treatment Market encompasses therapies and medications aimed at alleviating symptoms of panic disorders, including cognitive-behavioral therapy, antidepressants, and benzodiazepines. This market is driven by rising mental health awareness and increasing prevalence of anxiety disorders. Innovations focus on personalized treatment plans and digital therapeutics, with a growing emphasis on telehealth solutions to enhance accessibility and efficacy. The sector is poised for growth as societal destigmatization and healthcare advancements continue to evolve.

The Panic Attack Treatment Market is poised for robust growth, driven by increasing awareness and the rising prevalence of anxiety disorders. The pharmaceutical segment leads, with selective serotonin reuptake inhibitors (SSRIs) being the top-performing sub-segment due to their efficacy. Benzodiazepines follow closely, providing rapid relief for acute panic symptoms. Psychotherapy, particularly cognitive-behavioral therapy (CBT), is the second highest performing segment, gaining traction as a long-term treatment strategy. Emerging digital therapeutics, including mobile applications and teletherapy platforms, are gaining popularity, catering to the demand for accessible and convenient treatment options. The integration of virtual reality in therapy sessions is an innovative trend, offering immersive experiences to alleviate symptoms. Complementary and alternative therapies, such as mindfulness and yoga, are also gaining acceptance, enhancing overall well-being. The market is witnessing increased investment in research and development, focusing on personalized medicine approaches to optimize treatment outcomes and improve patient quality of life.

The Panic Attack Treatment Market is characterized by a diverse range of therapeutic options, including medications and cognitive therapies. Market share is primarily held by pharmaceutical giants, with pricing strategies aligning closely with brand reputation and efficacy. Recent product launches focus on innovative delivery methods and novel compounds, enhancing patient compliance and therapeutic outcomes. The market is witnessing a shift towards personalized treatment plans, driven by advancements in pharmacogenomics and digital health technologies. Competition within the Panic Attack Treatment Market is intense, with key players vying for dominance through strategic mergers and acquisitions. Benchmarking reveals a trend towards specialization and niche targeting. Regulatory frameworks, particularly in North America and Europe, are stringent, shaping market dynamics and influencing product approvals. Data privacy regulations impact digital therapy solutions, necessitating robust compliance strategies. The market is poised for growth, supported by increasing mental health awareness and technological innovations, despite challenges in regulatory compliance and competitive pressures.

Geographical Overview:

The Panic Attack Treatment Market is witnessing notable growth across diverse regions, each showcasing unique opportunities. North America leads the charge, driven by heightened awareness of mental health and substantial healthcare funding. The region's advanced healthcare infrastructure and increasing prevalence of anxiety disorders further bolster market expansion. Europe follows closely, with significant investments in mental health care and supportive government policies fostering a conducive environment for growth. The emphasis on innovative treatment approaches and research initiatives enhances the market's potential. In the Asia Pacific, the market is expanding rapidly, propelled by rising awareness and acceptance of mental health issues. Emerging economies like India and China are experiencing increased demand for effective treatment options, presenting lucrative opportunities for market players. Latin America and the Middle East & Africa are emerging growth pockets. These regions are recognizing the importance of mental health treatment, with increasing investments in healthcare infrastructure and awareness campaigns driving market growth.

The Panic Attack Treatment Market is influenced by global tariffs, geopolitical risks, and evolving supply chain dynamics. In Japan and South Korea, increasing tariffs and trade tensions with major economies are prompting investments in local pharmaceutical innovations and generic drug production. China's strategy focuses on bolstering domestic healthcare capabilities to mitigate the impact of international trade barriers. Taiwan, while a crucial player in pharmaceutical manufacturing, remains vulnerable to geopolitical tensions, particularly between the US and China. The global parent market for mental health treatment is expanding as awareness and diagnosis rates improve. By 2035, the market's growth will hinge on strategic regional partnerships and supply chain resilience. Middle East conflicts exacerbate global energy price volatility, indirectly affecting production and distribution costs in the healthcare sector.

Key Trends and Drivers:

The Panic Attack Treatment Market is experiencing robust growth, propelled by rising mental health awareness and increasing prevalence of anxiety disorders. Key trends include technological advancements in treatment methods, such as digital therapeutics and telemedicine, which are enhancing patient access and convenience. The integration of artificial intelligence in diagnostic tools is further refining treatment personalization, aligning with the growing demand for tailored healthcare solutions. Pharmaceutical innovations are driving market expansion, with novel drug formulations and non-invasive therapies gaining traction. The increasing acceptance of alternative therapies, like mindfulness and cognitive-behavioral therapy, underscores a shift towards holistic treatment approaches. Regulatory support and initiatives to destigmatize mental health issues are also pivotal drivers, fostering a more conducive environment for market growth. Moreover, the market is witnessing opportunities in emerging economies where mental health infrastructure is developing rapidly. Companies that can provide cost-effective and scalable treatment solutions are well-positioned to capitalize on these burgeoning markets. As awareness and acceptance of mental health treatment grow, the Panic Attack Treatment Market is poised for sustained expansion, particularly in regions prioritizing mental health as a critical component of overall well-being.

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Mode
• 2.8 Key Market Highlights by Stage

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Pharmacological Treatments
  • 4.1.2 Cognitive Behavioral Therapy
  • 4.1.3 Mindfulness-Based Therapy
  • 4.1.4 Exposure Therapy
  • 4.1.5 Acceptance and Commitment Therapy
  • 4.1.6 Psychodynamic Therapy
  • 4.1.7 Supportive Therapy
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 SSRIs
  • 4.2.2 SNRIs
  • 4.2.3 Benzodiazepines
  • 4.2.4 Beta-Blockers
  • 4.2.5 Antidepressants
  • 4.2.6 Therapeutic Apps
  • 4.2.7 Wearables
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 In-patient Treatment
  • 4.3.2 Out-patient Treatment
  • 4.3.3 Teletherapy
  • 4.3.4 Group Therapy
  • 4.3.5 Individual Therapy
  • 4.3.6 Emergency Services
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Mobile Health Technology
  • 4.4.2 Telemedicine Platforms
  • 4.4.3 AI-based Diagnostics
  • 4.4.4 Virtual Reality Therapy
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Acute Panic Attack Management
  • 4.5.2 Long-term Anxiety Management
  • 4.5.3 Relapse Prevention
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Hospitals
  • 4.6.2 Mental Health Clinics
  • 4.6.3 Homecare Settings
  • 4.6.4 Academic & Research Institutes
• 4.7 Market Size & Forecast by Mode (2020-2035)
  • 4.7.1 Prescription-based
  • 4.7.2 Over-the-counter
  • 4.7.3 Digital Platforms
• 4.8 Market Size & Forecast by Stage (2020-2035)
  • 4.8.1 Initial Diagnosis
  • 4.8.2 Treatment Initiation
  • 4.8.3 Maintenance
  • 4.8.4 Follow-up

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 End User
    • 5.2.1.7 Mode
    • 5.2.1.8 Stage
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 End User
    • 5.2.2.7 Mode
    • 5.2.2.8 Stage
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 End User
    • 5.2.3.7 Mode
    • 5.2.3.8 Stage
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 End User
    • 5.3.1.7 Mode
    • 5.3.1.8 Stage
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 End User
    • 5.3.2.7 Mode
    • 5.3.2.8 Stage
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 End User
    • 5.3.3.7 Mode
    • 5.3.3.8 Stage
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 End User
    • 5.4.1.7 Mode
    • 5.4.1.8 Stage
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 End User
    • 5.4.2.7 Mode
    • 5.4.2.8 Stage
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 End User
    • 5.4.3.7 Mode
    • 5.4.3.8 Stage
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 End User
    • 5.4.4.7 Mode
    • 5.4.4.8 Stage
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 End User
    • 5.4.5.7 Mode
    • 5.4.5.8 Stage
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 End User
    • 5.4.6.7 Mode
    • 5.4.6.8 Stage
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 End User
    • 5.4.7.7 Mode
    • 5.4.7.8 Stage
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 End User
    • 5.5.1.7 Mode
    • 5.5.1.8 Stage
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 End User
    • 5.5.2.7 Mode
    • 5.5.2.8 Stage
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 End User
    • 5.5.3.7 Mode
    • 5.5.3.8 Stage
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 End User
    • 5.5.4.7 Mode
    • 5.5.4.8 Stage
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 End User
    • 5.5.5.7 Mode
    • 5.5.5.8 Stage
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 End User
    • 5.5.6.7 Mode
    • 5.5.6.8 Stage
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 End User
    • 5.6.1.7 Mode
    • 5.6.1.8 Stage
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 End User
    • 5.6.2.7 Mode
    • 5.6.2.8 Stage
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 End User
    • 5.6.3.7 Mode
    • 5.6.3.8 Stage
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 End User
    • 5.6.4.7 Mode
    • 5.6.4.8 Stage
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 End User
    • 5.6.5.7 Mode
    • 5.6.5.8 Stage

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Mind Med
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Alkermes
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Sage Therapeutics
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Axsome Therapeutics
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Intra- Cellular Therapies
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Vista Gen Therapeutics
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Relmada Therapeutics
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Biohaven Pharmaceuticals
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Cerevel Therapeutics
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Karuna Therapeutics
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Minerva Neurosciences
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Otsuka Pharmaceutical
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Jazz Pharmaceuticals
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 H. Lundbeck
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Neurocrine Biosciences
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 ACADIA Pharmaceuticals
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Sunovion Pharmaceuticals
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Eisai
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Vanda Pharmaceuticals
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Supernus Pharmaceuticals
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us